Cystic Fibrosis

CTAF

Due to the COVID-19 pandemic, we have decided to indefinitely postpone our upcoming public meeting on modulator therapies for CF (originally slated for April 30).  We have also decided to extend the current public comment period and slightly delay the release of our revised evidence report.  The new dates are as follows:

- Public Comments now due 3/25 (originally 3/18)
- Evidence Report now posted on or about 4/27 (originally 4/9)

Key Dates

Associated Materials

09/06/2019 – 09/25/2019
Open Input Period

09/30/2019

09/30/2019 – 10/21/2019

09/30/2019

10/29/2019

12/05/2019

12/16/2019

02/20/2020

02/20/2020

02/20/2020 – 03/25/2020

04/27/2020

04/27/2020

04/27/2020

04/30/2020

Due to the COVID-19 pandemic, we have decided to indefinitely postpone our upcoming public  meeting on modulator therapies for CF (originally slated for April 30).

Meeting Agenda

04/30/2020

Due to the COVID-19 pandemic, we have decided to indefinitely postpone our upcoming public  meeting on modulator therapies for CF (originally slated for April 30).

Evidence Presentation

05/21/2020

Due to the COVID-19 pandemic, we have decided to indefinitely postpone our upcoming public  meeting on modulator therapies for CF (originally slated for April 30).

Final Evidence Report and Meeting Summary

05/21/2020

Due to the COVID-19 pandemic, we have decided to indefinitely postpone our upcoming public  meeting on modulator therapies for CF (originally slated for April 30).

Report-at-a-Glance